Roche's divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer (CHF 328.80, 0.00)
Weight Watchers Med+ establishes access to GLP-1s through Medicare GLP-1 Bridge Program ($16.40, 0.00)
Roche Holding announces FDA has accepted and granted priority review to supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of thyroid eye disease (CHF 338.80, 0.00)
Chugai Pharmaceutical receives Japan MHLW approval for additional indication of Avastin (¥7550.0000, 0)
FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma (CHF 327.80, 0.00)
BioMarin announces new three-year VOXZOGO data in Hypochondroplasia and BMN 333 early results at ENDO 2026 ($55.65, 0.00)
Goldman Sachs upgrades 4507.JP, 4519.JP
Chugai Pharmaceutical files additional indication application for Tecentriq as maintenance therapy (¥7450.0000, 0)
FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis ($1144.68, 0.00)
Eli Lilly présente des données sur Foundayo lors des 86e Sessions Scientifiques de l’ADA ($1131.42, 0.00)
Powered by FactSet Research Systems Inc.